This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Here's Why Retaining Cigna Stock is a Smart Move for Investors Now
by Zacks Equity Research
CI is well-poised for growth on the back of strong contributions from the Evernorth and Cigna Healthcare units. A strong financial position enables it to undertake business investments.
Here's Why Cigna (CI) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cigna Ends Humana Merger Speculation: CI Jumps 7.3% While HUM Slips
by Zacks Equity Research
CI reaffirms its 2024 outlook, projecting full-year adjusted EPS to be a minimum of $28.40.
Acadia Healthcare Shares Down 18.7% Despite Q3 Earnings Beat
by Zacks Equity Research
ACHC's better-than-expected third-quarter earnings benefit from higher patient days and improving volumes. Closing two facilities led the company to reduce its 2024 revenue guidance.
Select Medical Up 13.8% Since Q3 Earnings Top on Patient Day Growth
by Zacks Equity Research
SEM's strong third-quarter results benefit from improving patient days and admissions in the Rehabilitation Hospital segment. Elevated expenses partially offset the positives.
Here's Why Cigna (CI) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tenet Q3 Earnings Beat on Strong Ambulatory Unit, '24 EPS View Raised
by Zacks Equity Research
THC's Q3 results benefit from higher same-hospital admissions and Medicaid supplemental revenue gains. Cost-cutting measures help offset challenges from hospital divestitures.
Company News for Nov 1, 2024
by Zacks Equity Research
Companies In The Article Are: MET,CI, BMY, MO
Cigna (CI) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cigna Q3 Earnings Beat on Client Wins & Specialty Business Strength
by Zacks Equity Research
CI's strong third-quarter results benefit from a strong Evernorth Health Services segment. Higher expenses partially offset the positives.
Cigna (CI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 4.02% and 6.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will a Strong Evernorth Unit Benefit Cigna in Q3 Earnings?
by Zacks Equity Research
CI's Q3 results are likely to be aided by strength in the specialty pharmacy business, partly offset by elevated medical costs resulting from higher utilization trends.
Countdown to Cigna (CI) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Cigna (CI) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana and Molina Healthcare
by Zacks Equity Research
UnitedHealth, The Cigna, Humana and Molina Healthcare are part of the Zacks Industry Outlook article.
Top Stock Reports for AbbVie, ADP & Analog Devices
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Automatic Data Processing, Inc. (ADP) and Analog Devices, Inc. (ADI), as well as two micro-cap stocks Taylor Devices, Inc. (TAYD) and Village Super Market, Inc. (VLGEA).
Elevance Health's Q3 Earnings Miss Due to Medicaid Redeterminations
by Zacks Equity Research
ELV's third-quarter earnings are hurt by declining membership in Medicaid and Medicare, partially offset by improved product revenues.
4 HMO Stocks to Watch Despite Continued Industry Headwinds
by Zacks Equity Research
The Medical-HMO industry is aided by rising health insurance premiums and strategic M&A moves, but faces margin pressure from high-tech costs and staffing shortages. UNH, CI, HUM and MOH are likely to navigate industry storms.
UnitedHealth Q3 Earnings Beat on Domestic Commercial Business
by Zacks Equity Research
UNH's third-quarter earnings benefit on the back of client wins in the Optum Rx sub-unit, partly offset by an elevated operating expense level.
Elevance's Pre-Q3 Earnings Analysis: Smart Buy Now or Caution Ahead?
by Zacks Equity Research
ELV's third-quarter results are likely to reflect growing operating income from the Carelon business.
Why Cigna (CI) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Cigna (CI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.